Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

33%

Ph phase_1

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Other(1)

Detailed Status

unknown1

Recruiting1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 31 (33.3%)

N/A1 (33.3%)

Trials by Status

unknown133%

recruiting133%

completed133%

Recent Activity

1 active trials

Showing 3 of 3

completedphase_3

Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection

NCT02918955

recruitingnot_applicable

Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia

NCT05397262

unknownphase_1

AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy

NCT03308604

Clinical Trials (3)

Showing 3 of 3 trials

NCT02918955Phase 3

Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection

Completed

NCT05397262Not Applicable

Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia

Recruiting

NCT03308604Phase 1

AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy

Unknown

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3